Comments
Suven Life Sciences , a specialty biopharmaceutical company developing therapeutics in central nervous system diseases, on Thursday announced that the last patient has completed the last visit for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the topline data of this study at the Alzheimer’s Association International Conference on July 17 at Los Angeles. Shares of Suven Life moved up 3.4 per cent at ₹259.10 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.